CIK 0001595097
- Non-accelerated filer
- Smaller reporting company
Corbus Pharmaceuticals Holdings, Inc.
Sign in to watch- Ticker
- CRBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464348039
- Phone
- +1 617-963-0103
- Business address
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Former names
- SAV Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,758,438
- in 2 filings, $16K under 10b5-1 plans
Net −$1,758,438. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-29 | Cormorant Asset Management, LP Former 10% Owner | Sale | −425,000 | $4.10 | $1.7M | 1,919,971 |
| 2026-09-14 | Ben Yong Director | Sale 10b5-1 | −2,000 | $7.84 | $16K | 9,383 |
| 2026-08-16 | Nicacio Leonardo Viana Chief Medical Officer | Grant or award | +58,333 | 58,333 | ||
| 2026-08-16 | Nicacio Leonardo Viana Chief Medical Officer | Grant or award · Stock options (right to buy) | +191,676 | 191,676 | ||
| 2026-08-11 | Saxena Nishant C Chief Business Officer | Purchase | +2,600 | $9.63 | $25K | 77,900 |
| 2026-08-07 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −17,000 | $10.08 | $171K | 157,316 |
| 2026-08-07 | Moran Sean F. Chief Financial Officer | Sale 10b5-1 | −12,000 | $10.08 | $121K | 84,694 |
| 2026-06-10 | Kung Winston Director | Sale 10b5-1 | −2,026 | $7.91 | $16K | 12,140 |
| 2026-06-10 | Jenkins John Kenneth Director | Sale 10b5-1 | −4,800 | $7.91 | $38K | 3,833 |
| 2026-06-10 | Altmeyer Anne Director | Sale 10b5-1 | −2,412 | $7.91 | $19K | 7,579 |
| 2026-06-03 | Saxena Nishant C Chief Business Officer | Purchase | +9,000 | $7.58 | $68K | 75,300 |
| 2026-06-02 | Saxena Nishant C Chief Business Officer | Purchase | +4,500 | $7.33 | $33K | 66,300 |
| 2026-05-21 | Saxena Nishant C Chief Business Officer | Grant or award | +58,300 | 61,800 | ||
| 2026-05-21 | Saxena Nishant C Chief Business Officer | Grant or award · Stock options (right to buy) | +192,300 | 192,300 | ||
| 2026-05-19 | Kung Winston Director | Grant or award | +3,800 | 14,166 | ||
| 2026-05-19 | Kung Winston Director | Grant or award · Stock options (right to buy) | +12,300 | 12,300 | ||
| 2026-05-19 | Jacques Rachelle Suzanne Director | Grant or award | +3,800 | 11,383 | ||
| 2026-05-19 | Jacques Rachelle Suzanne Director | Grant or award · Stock options (right to buy) | +12,300 | 12,300 | ||
| 2026-05-19 | Jenkins John Kenneth Director | Grant or award | +3,800 | 8,633 | ||
| 2026-05-19 | Jenkins John Kenneth Director | Grant or award · Stock options (right to buy) | +12,300 | 12,300 |
Page 1 of 10 · 200 trades